Riociguat in the Treatment of Chronic Thromboembolic Pulmonary Hypertension: An Evidence-Based Review of Its Place in Therapy

References

• Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest. 1993;103(3):685–692. doi:10.1378/chest.103.3.685
   PubMed Web of Science ®Google Scholar
• Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(1):1801915. doi:10.1183/13993003.01915-2018
   PubMed Web of Science ®Google Scholar
• Simonneau G, Torbicki A, Dorfmüller P, Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir J. 2017;26(143):143. doi:10.1183/16000617.0112-2016
   Google Scholar
• Delcroix M, Kerr K, Fedullo P. Chronic thromboembolic pulmonary hypertension. epidemiology and risk factors. Ann Am Thorac Soc. 2016;13(Suppl 3):S201–S206. doi:10.1513/AnnalsATS.201509-621AS
   PubMed Web of Science ®Google Scholar
• Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124(18):1973–1981. doi:10.1161/CIRCULATIONAHA.110.015008
   PubMed Web of Science ®Google Scholar
• Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33(2):325–331. doi:10.1183/09031936.00087608
   PubMed Web of Science ®Google Scholar
• Matthews DT, Hemnes AR. Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension. Pulm Circ. 2016;6(2):145–154. doi:10.1086/686011
   PubMed Web of Science ®Google Scholar
• Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1). doi:10.1183/13993003.01913-2018.
   Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119. doi:10.1093/eurheartj/ehv317
   PubMed Web of Science ®Google Scholar
• Simonneau G, D’Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. 2015;45(5):1293–1302. doi:10.1183/09031936.00087114
   PubMed Web of Science ®Google Scholar
• Pesavento R, Prandoni P. Prevention and treatment of the chronic thromboembolic pulmonary hypertension. Thromb Res. 2018;164:150–156. doi:10.1016/j.thromres.2018.02.149
   PubMed Web of Science ®Google Scholar
• Tanabe N, Kawakami T, Satoh T, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: A systematic review. Respir Investig. 2018;56(4):332–341. doi:10.1016/j.resinv.2018.03.004
   PubMed Web of Science ®Google Scholar
• Tsuji A, Ogo T, Ueda J, et al. Predictors of residual pulmonary hypertension after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2017;226:118–120. doi:10.1016/j.ijcard.2016.09.132
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319–329. doi:10.1056/NEJMoa1209657
   PubMed Web of Science ®Google Scholar
• Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation. 2000;102(14):1718–1723. doi:10.1161/01.CIR.102.14.1718
   PubMed Web of Science ®Google Scholar
• Moncada S, Radomski MW, Palmer RM. Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol. 1988;37(13):2495–2501. doi:10.1016/0006-2952(88)90236-5
   PubMed Web of Science ®Google Scholar
• Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263–2273. doi:10.1161/CIRCULATIONAHA.110.981738
   PubMed Web of Science ®Google Scholar
• Sandner P, Becker-Pelster EM, Stasch JP. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases. Nitric Oxide. 2018;77:88–95. doi:10.1016/j.niox.2018.05.001
   PubMed Web of Science ®Google Scholar
• Conole D, Scott LJ. Riociguat: first global approval. Drugs. 2013;73(17):1967–1975. doi:10.1007/s40265-013-0149-5
   PubMed Web of Science ®Google Scholar
• Khaybullina D, Patel A, Zerilli T. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014;39(11):749–758.
   PubMedGoogle Scholar
• Ghofrani HA, Humbert M, Langleben D, et al. Riociguat: mode of action and clinical development in pulmonary hypertension. Chest. 2017;151(2):468–480. doi:10.1016/j.chest.2016.05.024
   PubMed Web of Science ®Google Scholar
• Frey R, Becker C, Saleh S, Unger S, van der Mey D, Clinical Pharmacokinetic MW. Pharmacodynamic profile of Riociguat. Clin Pharmacokinet. 2018;57(6):647–661. doi:10.1007/s40262-017-0604-7
   PubMed Web of Science ®Google Scholar
• Saleh S, Becker C, Frey R, Mück W. Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Pulm Circ. 2016;6(Suppl 1):S86–S96. doi:10.1086/685404
   PubMedGoogle Scholar
• Benza RL, Farber HW, Frost A, et al. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. J Heart Lung Transplant. 2018;37(7):836–843. doi:10.1016/j.healun.2018.02.015
   PubMed Web of Science ®Google Scholar
• Halank M, Hoeper MM, Ghofrani HA, et al. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: results from a phase II long-term extension study. Respir Med. 2017;128:50–56. doi:10.1016/j.rmed.2017.05.008
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Jansa P, Nielsen-Kudsk JE, et al. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulm Med. 2017;17(1):216. doi:10.1186/s12890-017-0563-7
   PubMedGoogle Scholar
• Wiedenroth CB, Ghofrani HA, Adameit MSD, et al. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulm Circ. 2018;8(3):2045894018783996.
   Web of Science ®Google Scholar
• Weir NA, Conrey A, Lewis D, Mehari A. Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: a case series. Pulm Circ. 2018;8(4):2045894018791802. doi:10.1177/2045894018791802
   Web of Science ®Google Scholar
• Gall H, Vachiéry JL, Tanabe N, et al. Real-world switching to Riociguat: management and practicalities in patients with PAH and CTEPH. Lung. 2018;196(3):305–312. doi:10.1007/s00408-018-0100-3
   PubMed Web of Science ®Google Scholar
• Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T. Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population. Appl Health Econ Health Policy. 2011;9(6):377–387. doi:10.2165/11592440-000000000-00000
   PubMedGoogle Scholar
• Said Q, Martin BC, Joish VN, Kreilick C, Mathai SC. The cost to managed care of managing pulmonary hypertension. J Med Econ. 2012;15(3):500–508. doi:10.3111/13696998.2012.665109
   PubMedGoogle Scholar
• Chapman R, Quon P, Brand S, Sikirica M, Joish VN. Cost-effectiveness of riociguat for the treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in the United States. In: A56. Pulmonary Embolism: Acute and Chronic; 2014:A1872.
   Google Scholar
• CADTH Common Drug Reviews. Pharmacoeconomic Review Report: Riociguat (Adempas). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. Copyright © 2015 Canadian Agency for Drugs and Technologies in Health; 2015.
   Google Scholar
• Burudpakdee C, Shah A, Joish VN, Divers C, Yaldo A. Budgetary impact of adding riociguat to a US health plan for the treatment of patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Am Health Drug Benefits. 2014;7(9):479–487.
   PubMedGoogle Scholar